Tissue Repair

GHK-Cu

Research Reagent · Laboratory Use Only

Quick Answer

What does the research show about GHK-Cu peptide and its biological activity?

GHK-Cu (copper peptide glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide studied for roles in wound healing, collagen synthesis, and antioxidant activity. Research published in PubMed-indexed journals, including work by Pickart et al., suggests it activates tissue remodelling pathways and exhibits anti-inflammatory properties. Studies remain largely preclinical; human clinical evidence is still limited.

PMID41476424↗DOI10.1155/2015/648108↗⟳ Reconstitution Calculator

Scientific AbstractPMID 41476424 · 2026

Background

Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides.

Purpose

To evaluate the current evidence and applications of injectable peptide therapy, focusing on its potential in regenerative medicine and sports performance, to help orthopaedic providers better understand the current state of different therapeutic peptide approaches.

Study Design

Narrative review.

Methods

A comprehensive literature search was conducted using PubMed to identify biochemical and clinical studies on the most popular types of injectable peptide therapy. Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu.

Results

BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability. TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports. CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies. Tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions.

Conclusion

While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Despite the popularity of these peptides in mainstream media and among patients, significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients.

Source:10.1155/2015/648108

Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is GHK-Cu?

GHK-Cu (Glycine-Histidine-Lysine Copper peptide) is a tripeptide-copper complex that demonstrates collagen synthesis stimulation and anti-inflammatory properties in preclinical models. Current clinical evidence for musculoskeletal applications remains absent, limiting its therapeutic validation in orthopedic contexts.

Mechanism of Action

GHK-Cu functions through copper ion-mediated regulation of cellular signaling pathways involved in collagen biosynthesis and tissue remodeling. The peptide complex enhances angiogenesis and modulates inflammatory cascade responses by upregulating growth factors and suppressing pro-inflammatory cytokines. Copper facilitates oxidative stress management through superoxide dismutase activity, supporting cellular repair mechanisms at the molecular level.

Observed Laboratory Results

Wound healing promotion: Preclinical studies documented accelerated re-epithelialization and enhanced dermal matrix deposition in tissue culture and animal wound models
Anti-inflammatory activity: GHK-Cu demonstrated dose-dependent reduction in inflammatory markers through modulation of NF-κB signaling pathways
Collagen upregulation: In vitro assays showed increased Type I and Type III collagen expression in fibroblast cultures exposed to the peptide complex

Critical Gap in Evidence

No human clinical trials or orthopaedic-specific studies validate GHK-Cu efficacy for musculoskeletal injury, degenerative joint disease, or sports medicine applications. Dosing protocols, optimal delivery mechanisms, and safety profiles remain undefined for clinical use.

Clinical Research Parameters

2 trials

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Registered Clinical Trials

ClinicalTrials.gov ↗

NCT05932732 ↗

COMPLETEDPhase IVn=27

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

This is a phase IV, unblinded, open-label study assessing the impact on skin quality, hydration, and barrier of three (3) Hydrafacial treatments in healthy adults of Fitzpatrick Skin Types I \& II, III, IV, V \& VI, 30 to 55 years of age. Efficacy and subject satisfaction will be assessed, before and after three (3) HF treatments, in 6 patient cohorts, each cohort defined by FST I-VI.

Study Interventions

HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System

Primary Endpoints

Change in skin facial skin elasticity, wrinkles, roughness, fine lines, pigmentation, erythema, and pore size; Change in facial aesthetic appearance

Study Period

2023-11-20 → 2024-10-09

NCT07437586 ↗

RECRUITINGPhase IIn=60

Topical GHK-Cu Gel for Acute Skin Wound Healing

This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel. Participants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds wi

Study Interventions

GHK-Cu Gel (Copper(II)-peptide complex), vehicle Gel (placebo comparator)

Primary Endpoints

Time to complete re-epithelialization (days) of each wound, defined as 100% epithelial coverage without drainage, confirmed by blinded clinical assessment and standardized photography.

Study Period

2026-02-02 → 2028-03-17

Research Compliance Notice

All data presented on this page is for laboratory research purposes only. GHK-Cu is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 41476424) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

BPC-157

Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from gastri…

→

TB-500

BACKGROUND: Therapeutic peptides are short-chain amino acids that regulate cellular functi…

→

Ara-290

PURPOSE: Polymorphism and mutations of human leukocyte antigens (HLAs) and calreticulin ar…

→

AOD-9604

The analysis of low-molecular-mass peptides in doping controls has become a mandatory aspe…